The Current Ratio as of July 2024 (TTM) for Akero Therapeutics, Inc. (AKRO) is 30.12

According to Akero Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 30.12. This represents a change of 10.10% compared to the average of 27.35 of the last 4 quarters.

Akero Therapeutics, Inc. (AKRO) Historical Current Ratio (quarterly & annually)

How has AKRO Current Ratio performed in the past?

The mean historical Current Ratio of Akero Therapeutics, Inc. over the last ten years is 18.12. The current 30.12 Current Ratio has changed 16.52% with respect to the historical average. Over the past ten years (40 quarters), AKRO's Current Ratio was at its highest in in the June 2019 quarter at 34.41. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Akero Therapeutics, Inc. (AKRO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Akero Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Akero Therapeutics, Inc. (AKRO) Average Current Ratio

How has AKRO Current Ratio performed in the past?

The current Current Ratio of Akero Therapeutics, Inc. (AKRO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Akero Therapeutics, Inc. (AKRO) Current Ratio vs. Peers

How is AKRO’s Current Ratio compared to its peers?

Akero Therapeutics, Inc.’s Current Ratio is greater than Terns Pharmaceuticals, Inc. (27.85), greater than Madrigal Pharmaceuticals, Inc. (9.39), greater than Inozyme Pharma, Inc. (14.05), less than Viking Therapeutics, Inc. (37.69), greater than Intercept Pharmaceuticals, Inc. (4.22), greater than Reata Pharmaceuticals, Inc. (3.21), greater than Revolution Medicines, Inc. (18.45), greater than Avidity Biosciences, Inc. (12.47), greater than Protagonist Therapeutics, Inc. (15.72), greater than Stoke Therapeutics, Inc. (5.42), less than TCR2 Therapeutics Inc. (0), greater than Black Diamond Therapeutics, Inc. (2.96), greater than Atreca, Inc. (7.05), greater than Passage Bio, Inc. (1.58), greater than null (8.43),

Build a custom stock screener for Akero Therapeutics, Inc. (AKRO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akero Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Akero Therapeutics, Inc. (AKRO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Akero Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.